Chronic Airway Infections
Softox Solutions AS focuses on chronic airway infections, with research centered on patients affected by persistent bacterial burden in the respiratory tract. Its clinical activity includes work in cystic fibrosis, primary ciliary dyskinesia, and non-cystic fibrosis bronchiectasis, reflecting interest in difficult-to-treat infectious disease settings within pulmonary medicine.
- Sputum bacterial density
- Respiratory infection control
- Airway microbiological burden
The sponsor’s research interest is directed toward inhaled treatment approaches for reducing bacterial load in the lower airways and addressing persistent infection-related symptoms in chronic respiratory disease.
Respiratory Therapeutics
The sponsor is active in respiratory therapeutics involving nebulised administration and local airway delivery. Its funded research examines treatment use in the context of chronic infection of the airways, where maintaining tolerability and respiratory safety is central to development in inhalation therapy.
- Nebulised delivery
- Inhaled airway treatment
- Local pulmonary administration
This area of interest places emphasis on therapies intended for direct action within the respiratory tract rather than systemic exposure.
Airway Infection Biomarkers
Research activity also extends to microbiological markers associated with airway infection, particularly measures of bacterial presence in sputum. These endpoints are relevant to understanding treatment effects in chronic respiratory infection and monitoring changes in airway colonisation.
- Sputum culture measures
- Bacterial colony counts
- Microbial load assessment
The sponsor’s clinical interest includes objective indicators of infection severity within the respiratory tract.
Safety and Tolerability in Healthy Volunteers
Softox Solutions AS also supports research involving healthy participants to assess safety and tolerability of repeated nebulised administration. This work relates to early clinical evaluation of respiratory agents intended for chronic airway disease.
- Repeated administration
- Adverse event monitoring
- Respiratory tolerability
These interests connect formulation development with clinical use in patients who have ongoing airway infection.
